Results 1 to 10 of about 183 (85)
Association of Vitamin K and Non‐Vitamin K Oral Anticoagulant Use and Cancer Incidence in Atrial Fibrillation Patients
Clinical Pharmacology &Therapeutics, Volume 111, Issue 1, Page 200-208, January 2022., 2022 The association between the use of vitamin K antagonists (VKAs) and cancer risk reduction remains unclear. We aimed to assess the association between the use of VKAs or direct oral anticoagulants (DOACs) and the incidence of cancer in a large cohort of patients with atrial fibrillation (AF) by means of a population‐based, propensity‐weighted cohort ...Adina A. Iftimi, Clara L. Rodríguez‐Bernal, Salvador Peiró, Santiago Bonanad, Andreu Ferrero‐Gregori, Isabel Hurtado, Aníbal García‐Sempere, Gabriel Sanfélix‐Gimeno +7 morewiley +1 more sourceEuropean Registry on Helicobacter pylori management: Single‐capsule bismuth quadruple therapy is effective in real‐world clinical practice
United European Gastroenterology Journal, Volume 9, Issue 1, Page 38-46, February 2021., 2021 Abstract Background
There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks to a three‐in‐one single‐capsule formulation.Olga P. Nyssen, Angeles Perez‐Aisa, Manuel Castro‐Fernandez, Rinaldo Pellicano, Jose M. Huguet, Luis Rodrigo, Juan Ortuñ, o, Blas J. Gomez‐Rodriguez, Ricardo M. Pinto, Miguel Areia, Monica Perona, Oscar Nuñez, Marco Romano, Antonietta G. Gravina, Liliana Pozzati, Miguel Fernandez‐Bermejo, Marino Venerito, Peter Malfertheiner, Luis Fernanadez‐Salazar, Antonio Gasbarrini, Dino Vaira, Ignasi Puig, Francis Megraud, Colm O'Morain, Javier P. Gisbert, on behalf of The Hp‐EuReg investigators +26 morewiley +1 more sourceRole of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori management
United European Gastroenterology Journal, Volume 12, Issue 6, Page 691-704, July 2024.Abstract Background
Adherence to Helicobacter pylori (H. pylori) eradication treatment is a cornerstone for achieving adequate treatment efficacy. Objective
To determine which factors influence compliance with treatment. Methods
A systematic prospective non‐interventional registry (Hp‐EuReg) of the clinical practice of European gastroenterologists ...Jose M. Huguet, Luis Ferrer‐Barceló, Patrícia Suárez, Susana Barcelo‐Cerda, Javier Sempere, Ilaria Maria Saracino, Giulia Fiorini, Dino Vaira, Ángeles Pérez‐Aísa, Laimas Jonaitis, Bojan Tepes, M. Castro‐Fernandez, Manuel Pabón‐Carrasco, Alma Keco‐Huerga, Irina Voynovan, Alfredo J. Lucendo, Ángel Lanas, Samuel J. Martínez‐Domínguez, Enrique Alfaro Almajano, Luis Rodrigo, Ludmila Vologzanina, Dmitry S. Bordin, Antonio Gasbarrini, Gülüstan Babayeva, Frode Lerang, Mārcis Leja, Juozas Kupčinskas, Theodore Rokkas, Ricardo Marcos‐Pinto, Antonio Meštrović, Oleksiy Gridnyev, Perminder S. Phull, Sinead M. Smith, Doron Boltin, György Miklós Buzás, Jan Kral, Halis Şimşek, Tamara Matysiak‐Budnik, Vladimir Milivojevic, Wojciech Marlicz, Marino Venerito, Lyudmila Boyanova, Michael Doulberis, Lisette G. Capelle, Anna Cano‐Català, Leticia Moreira, Olga P. Nyssen, Francis Mégraud, Colm O’Morain, Javier P. Gisbert, on behalf of the Hp‐EuReg Investigators +50 morewiley +1 more sourceRole of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management
United European Gastroenterology Journal, Volume 12, Issue 1, Page 122-138, February 2024.Abstract Background
Management of Helicobacter pylori (H. pylori) infection requires co‐treatment with proton pump inhibitors (PPIs) and the use of antibiotics to achieve successful eradication. Aim
To evaluate the role of dosage of PPIs and the duration of therapy in the effectiveness of H. pylori eradication treatments based on the ‘European Registry Manuel Pabón‐Carrasco, Alma Keco‐Huerga, Manuel Castro‐Fernández, Ilaria Maria Saracino, Giulia Fiorini, Dino Vaira, Ángeles Pérez‐Aísa, Bojan Tepes, Laimas Jonaitis, Irina Voynovan, Alfredo J. Lucendo, Ángel Lanas, Samuel J. Martínez‐Domínguez, Enrique Alfaro Almajano, Luis Rodrigo, Ludmila Vologzanina, Natasa Brglez Jurecic, Maja Denkovski, Luis Bujanda, Rustam A. Abdulkhakov, Jose M. Huguet, Luis Fernández‐Salazar, Noelia Alcaide, Benito Velayos, Aiman Silkanovna Sarsenbaeva, Oleg Zaytsev, Tatiana Ilchishina, Jesús Barrio, Igor Bakulin, Monica Perona, Sergey Alekseenko, Marco Romano, Antonietta G. Gravina, Óscar Núñez, Blas José Gómez Rodríguez, Diego Ledro‐Cano, Rinaldo Pellicano, Pavel Bogomolov, Manuel Domínguez‐Cajal, Pedro Almela, Judith Gomez‐Camarero, Dmitry S. Bordin, Antonio Gasbarrini, Juozas Kupčinskas, Anna Cano‐Català, Leticia Moreira, Olga P. Nyssen, Francis Mégraud, Colm O’Morain, Javier P. Gisbert, on behalf of the Hp‐EuReg Investigators, Javier Tejedor‐Tejada, Galina Tarasova, Natalia Nikolaevna Dekhnich, Alfredo Di Leo, Giuseppe Losurdo, Miguel Fernández‐Bermejo, Eduardo Iyo, Fernando Bermejo, Alicia Algaba, Ludmila Grigorieva, Luis Javier Lamuela Calvo, Itxaso Jiménez, Boris D. Starostin, Natalia Baryshnikova, Luisa C. de la Peña‐Negro, Montserrat Planella, Consuelo Ramirez, Natalia V. Bakanova, Fabio Farinati, Matteo Ghisa, Teresa Angueira, Alla Kononova, Ana Campillo, Ramón Pajares Villarroya, Barbara Gomez, Liya Nikolaevna Belousova, Debora Compare, Javier Alcedo, Diego Burgos‐Santamaría, Francisco‐José Rancel‐Medina, Isabel Pérez‐Martínez, Igor Maev, Dmitrii Andreev, Jesús M. González‐Santiago, José Xavier Segarra Ortega, Virginia Flores, Antonio Cuadrado‐Lavín, Luis Hernández +88 morewiley +1 more source
